CYduct Diagnostics Inc (CYDX)

[blueskies]

MORE FACTS:

"Going forward, Solos management plans to use its resources to increase sales either organically or through mergers and acquisitions with the ultimate goal of achieving long term sustained profitability for its shareholders."

"Backed by technical support, Solos’ knowledgeable sales team can help make the right buying decisions for the hospital, surgery center, or physician office as well as to support the many systems in the field across the United States"

"Today, Solos Endoscopy is positioned for tremendous growth in the multi-billion dollar endoscopic market. Solos Endoscopy currently has its endoscopic instruments in over 67 hospitals in the United States with plans to market its endoscopic instrument internationally upon receiving its CE Mark"

"Expert Resource will attend the final audit, and help interpret any findings. According to Expert Resource, their consultants maintain a 100% success rate of passing the final audit on the first attempt."

Solos Endoscopy and TUV SUD America Schedule Stage 2 ISO 13485 Audit for August 16, 2013
http://www.otcmarkets.com/stock/SNDY/news/Solos-Endoscopy-and-TUV-SUD-America-Schedule-Stage-2-ISO-13485-Audit-for-August-16--2013?id=64413&b=y

"Solos has several exciting new advances in product development that will change the way minimally invasive procedures are utilized in the medical field in order to treat and prevent disease."

"The demand for endoscope services is increasing due to an increase in the aging and chronically ill population worldwide. Advancements in endoscopic technologies and inclusion of various types of lighting sources, video cameras, real-time conversion of data into three-dimensional images are also driving this market.

http://www.olea-medical.com/en_US/homepage.html ???

http://www.sierraworldequityreview.com/2013/07/19/solos-endoscopy-sndy-surges-80-as-joint-venture-talks-with-olea-medical-happen-in-cambridge-massachusetts-ventures-sierra-world-equity-review/ ????


"Endoscopy procedures have become highly effective in the diagnosis, treatment, and management of cancer patients. Many now consider endoscopy to have become the gold standard for cancer diagnosis and treatment, as well as for many other medical
conditions. The MammoView instrument line, designed exclusively for breast endoscopy has become crucial to early breast cancer screening as a method to significantly reduce breast cancer death
rates. The Solos MammoView Breast Endoscopy System is designed to distinguish and inspect suspicious pre-cancerous lesions undetectable by other methods as well as complement existing
diagnosis and treatment options with direct endoscopic observation. The Solos MammoView system is currently in use at various teaching hospitals across the United States."

http://solosendoscopy.com/SNDY_PresidentsLetter.pdf

Jul 18, 2013 (ACCESSWIRE via COMTEX) -- BOSTON, MA, July 18, 2013 - (eTeligis via ACCESSWIRE) - Solos Endoscopy, Inc. (OTC PINK: SNDY) is pleased to announce that the Company's MammoView(R) Breast Endoscopy System can aid in giving women the best prognosis for recovery by detecting breast cancer at an earlier stage than conventional methods (www.solosendoscopy.com/ductoscope-sell-sheet-final.pdf).

Aug 02, 2013 (ACCESSWIRE via COMTEX) -- BOSTON, August 2, 2013 - Solos Endoscopy, Inc. (OTC PINK: SNDY) is pleased to announce that the Company has retained Emergo Group to act as the Company's authorized representative in Europe.

Blueskies and Good Luck All